GlassScriptPhysician profile
Timothy Raymond Byrnes
NPI 1245234715
$6,804.07
in general payments reported to CMS, 2019-2025
22 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what 76% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $408 · 2021: $453 · 2022: $715 · 2023: $529 · 2024: $3,276 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,679 · Food and Beverage: $2,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,678.50 |
| Food and Beverage | $2,238.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $2,678.50 | 2023-2024 | Istent Trabecular Micro-Bypass System Model Is3, Kxl System (Not Refurbished), Istent Infinite Trabecular Micro-Bypass System Model Is3 |
| Regeneron Healthcare Solutions, INC. | $874.41 | 2019-2025 | Eylea Hd |
| Genentech USA, INC. | $604.16 | 2019-2025 | Vabysmo |
| Abbvie INC. | $603.89 | 2022-2025 | Ozurdex |
| Astellas Pharma US INC | $342.25 | 2024-2025 | Izervay |
| Bausch & Lomb Americas INC. | $320.09 | 2022-2025 | Xipere, Stellaris |
| Allergan, INC. | $264.37 | 2019-2021 | |
| Alimera Sciences, INC. | $251.17 | 2019-2024 | Yutiq, Iluvien |
| Regeneron Pharmaceuticals, INC. | $209.91 | 2025 | Eylea Hd |
| Apellis Pharmaceuticals, INC. | $187.74 | 2023-2025 | Syfovre |
| Biogen, INC. | $60.65 | 2022 | |
| Eyepoint US, INC. | $59.22 | 2021-2022 | |
| Harrow Eye, LLC | $57.70 | 2024-2025 | Iheezo, Triesence |
| Notal Vision, INC. | $57.42 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $54.06 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $48.39 | 2021 | |
| Novartis Pharmaceuticals Corporation | $37.55 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $26.69 | 2025 | Iluvien |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Coherus Oncology, INC. | $19.05 | 2023 | |
| Rayner Intraocular Lenses Limited | $14.11 | 2025 | Omidria |
| Spark Therapeutics, INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Byrnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.